<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>GLP-1 and Heart Health: What the SELECT Trial Actually Proved – Élan Clinic</title>
  <meta name="description" content="The SELECT trial enrolled 17,604 people and found a 20% reduction in major cardiovascular events with semaglutide. A physician explains what it actually proved — and what it didn't." />
  <link rel="canonical" href="https://elan.clinic/blog/glp1-heart-health-select-trial.html" />
  <link rel="icon" type="image/svg+xml" href="/favicon.svg" />

  <!-- Open Graph -->
  <meta property="og:type" content="article" />
  <meta property="og:url" content="https://elan.clinic/blog/glp1-heart-health-select-trial.html" />
  <meta property="og:title" content="GLP-1 and Heart Health: What the SELECT Trial Actually Proved" />
  <meta property="og:description" content="The SELECT trial enrolled 17,604 people and found a 20% reduction in major cardiovascular events with semaglutide. A physician explains what it proved — and what it didn't." />
  <meta property="og:locale" content="en_GB" />
  <meta property="article:published_time" content="2026-03-01" />
  <meta property="article:author" content="Dr. Ingmar Lindström" />

  <!-- Schema.org MedicalWebPage -->
  <script type="application/ld+json">
  {
    "@context": "https://schema.org",
    "@type": "MedicalWebPage",
    "name": "GLP-1 and Heart Health: What the SELECT Trial Actually Proved",
    "headline": "GLP-1 and Heart Health: What the SELECT Trial Actually Proved",
    "url": "https://elan.clinic/blog/glp1-heart-health-select-trial.html",
    "datePublished": "2026-03-01",
    "inLanguage": "en",
    "description": "The SELECT trial enrolled 17,604 people and found a 20% reduction in major cardiovascular events with semaglutide. A physician explains what it actually proved — and what it didn't.",
    "about": {
      "@type": "MedicalCondition",
      "name": "Cardiovascular Disease"
    },
    "medicalAudience": {
      "@type": "MedicalAudience",
      "audienceType": "Patient"
    },
    "author": {
      "@type": "Person",
      "name": "Dr. Ingmar Lindström",
      "jobTitle": "Physician",
      "worksFor": {
        "@type": "MedicalClinic",
        "name": "Élan Clinic",
        "url": "https://elan.clinic"
      }
    },
    "publisher": {
      "@type": "MedicalClinic",
      "name": "Élan Clinic",
      "url": "https://elan.clinic",
      "logo": "https://elan.clinic/favicon.svg",
      "telephone": "+37252999399",
      "address": {
        "@type": "PostalAddress",
        "streetAddress": "Sepapaja 12/1",
        "addressLocality": "Tallinn",
        "postalCode": "11415",
        "addressCountry": "EE"
      }
    },
    "mainEntityOfPage": {
      "@type": "WebPage",
      "@id": "https://elan.clinic/blog/glp1-heart-health-select-trial.html"
    },
    "citation": [
      {
        "@type": "ScholarlyArticle",
        "name": "SELECT trial: Semaglutide and cardiovascular outcomes in obesity without diabetes",
        "isPartOf": { "@type": "Periodical", "name": "New England Journal of Medicine" },
        "datePublished": "2023"
      }
    ]
  }
  </script>

  <!-- Google Fonts -->
  <link rel="preconnect" href="https://fonts.googleapis.com" />
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin />
  <link href="https://fonts.googleapis.com/css2?family=Playfair+Display:ital,wght@0,400;0,500;0,600;0,700;1,400;1,500&family=Inter:wght@300;400;500;600&display=swap" rel="stylesheet" />

  <style>
    *, *::before, *::after { box-sizing: border-box; margin: 0; padding: 0; }
    html { scroll-behavior: smooth; font-size: 16px; }
    body {
      font-family: 'Inter', sans-serif;
      background-color: #0D1B2A;
      color: rgba(232, 228, 222, 0.55);
      line-height: 1.7;
      -webkit-font-smoothing: antialiased;
    }
    h1, h2, h3, h4 { font-family: 'Playfair Display', serif; color: #E8E4DE; line-height: 1.2; font-weight: 500; }
    a { color: #C5A55A; text-decoration: none; }
    a:hover { text-decoration: underline; }
    .container { width: 100%; max-width: 1200px; margin: 0 auto; padding: 0 24px; }
    .label { display: inline-block; font-family: 'Inter', sans-serif; font-size: 0.7rem; font-weight: 600; letter-spacing: 0.18em; text-transform: uppercase; color: #C5A55A; margin-bottom: 20px; }
    .gold-line { width: 48px; height: 2px; background: #C5A55A; margin: 28px 0; }
    .nav { position: fixed; top: 0; left: 0; right: 0; z-index: 100; padding: 20px 24px; display: flex; align-items: center; justify-content: space-between; background: rgba(13, 27, 42, 0.92); backdrop-filter: blur(12px); border-bottom: 1px solid rgba(197, 165, 90, 0.12); }
    .nav__logo { font-family: 'Playfair Display', serif; font-size: 1.25rem; color: #E8E4DE; letter-spacing: 0.06em; text-decoration: none; }
    .nav__logo span { color: #C5A55A; }
    .nav__links { display: flex; align-items: center; gap: 32px; list-style: none; }
    .nav__links a { font-size: 0.78rem; font-weight: 500; letter-spacing: 0.1em; text-transform: uppercase; color: rgba(232, 228, 222, 0.65); text-decoration: none; transition: color 0.2s; }
    .nav__links a:hover, .nav__links a.active { color: #C5A55A; }
    .breadcrumb { padding: 120px 0 0; background-color: #0D1B2A; }
    .breadcrumb__inner { display: flex; align-items: center; gap: 8px; flex-wrap: wrap; }
    .breadcrumb__item { font-size: 0.75rem; font-weight: 500; letter-spacing: 0.08em; color: rgba(232, 228, 222, 0.4); text-transform: uppercase; }
    .breadcrumb__item a { color: rgba(232, 228, 222, 0.4); text-decoration: none; transition: color 0.2s; }
    .breadcrumb__item a:hover { color: #C5A55A; text-decoration: none; }
    .breadcrumb__sep { font-size: 0.7rem; color: rgba(197, 165, 90, 0.4); }
    .breadcrumb__item--current { color: #C5A55A; }
    .article-header { padding: 48px 0 64px; background-color: #0D1B2A; position: relative; overflow: hidden; }
    .article-header::before { content: ''; position: absolute; top: -100px; right: -150px; width: 500px; height: 500px; background: radial-gradient(circle, rgba(197,165,90,0.05) 0%, transparent 70%); pointer-events: none; }
    .article-header__content { max-width: 780px; }
    .article-header h1 { font-size: clamp(2rem, 4.5vw, 3.2rem); line-height: 1.15; margin-bottom: 28px; }
    .article-meta { display: flex; align-items: center; flex-wrap: wrap; gap: 24px; padding-top: 24px; border-top: 1px solid rgba(197, 165, 90, 0.15); }
    .article-meta__item { display: flex; align-items: center; gap: 8px; font-size: 0.8rem; color: rgba(232, 228, 222, 0.5); }
    .article-meta__item strong { color: rgba(232, 228, 222, 0.75); font-weight: 500; }
    .article-meta__dot { width: 3px; height: 3px; border-radius: 50%; background: rgba(197, 165, 90, 0.4); }
    .article-body { padding: 0 0 100px; background-color: #0D1B2A; }
    .article-body__inner { max-width: 780px; }
    .article-body p { font-size: 1.05rem; color: rgba(232, 228, 222, 0.72); line-height: 1.85; margin-bottom: 28px; }
    .article-body h2 { font-size: clamp(1.5rem, 2.5vw, 2rem); margin: 56px 0 20px; color: #E8E4DE; }
    .article-body h3 { font-size: clamp(1.1rem, 2vw, 1.35rem); margin: 40px 0 16px; color: #E8E4DE; }
    .article-body strong { color: rgba(232, 228, 222, 0.9); font-weight: 600; }
    .article-body em { color: rgba(232, 228, 222, 0.65); font-style: italic; }
    .article-body hr { border: none; height: 1px; background: rgba(197, 165, 90, 0.15); margin: 48px 0; }
    .pull-quote { border-left: 3px solid #C5A55A; padding: 20px 32px; margin: 40px 0; background: rgba(197, 165, 90, 0.04); }
    .pull-quote p { font-family: 'Playfair Display', serif; font-size: 1.2rem !important; font-style: italic; color: rgba(232, 228, 222, 0.82) !important; line-height: 1.6 !important; margin: 0 !important; }
    .key-stat { background: #111D2E; border: 1px solid rgba(197, 165, 90, 0.18); padding: 32px 36px; margin: 40px 0; }
    .key-stat__number { font-family: 'Playfair Display', serif; font-size: 3rem; color: #C5A55A; line-height: 1; margin-bottom: 8px; }
    .key-stat__label { font-size: 0.88rem; color: rgba(232, 228, 222, 0.6); line-height: 1.5; }
    .article-sources { margin-top: 60px; padding-top: 32px; border-top: 1px solid rgba(197, 165, 90, 0.12); }
    .article-sources p { font-size: 0.82rem !important; color: rgba(232, 228, 222, 0.38) !important; line-height: 1.6 !important; margin-bottom: 8px !important; }
    .article-sources .sources-label { font-size: 0.7rem; font-weight: 600; letter-spacing: 0.15em; text-transform: uppercase; color: #C5A55A; margin-bottom: 16px; display: block; }
    .back-link { display: inline-flex; align-items: center; gap: 8px; font-size: 0.78rem; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: rgba(232, 228, 222, 0.5); text-decoration: none; transition: color 0.2s, gap 0.2s; margin-bottom: 60px; }
    .back-link:hover { color: #C5A55A; gap: 12px; text-decoration: none; }
    .footer-cta { background-color: #111D2E; border-top: 1px solid rgba(197, 165, 90, 0.12); text-align: center; padding: 100px 24px; }
    .footer-cta h2 { max-width: 620px; margin: 0 auto 24px; font-size: clamp(1.6rem, 3vw, 2.2rem); }
    .footer-cta__sub { max-width: 480px; margin: 0 auto 40px; font-size: 0.95rem; }
    .btn { display: inline-block; padding: 16px 36px; font-family: 'Inter', sans-serif; font-size: 0.85rem; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; border: 1.5px solid #C5A55A; color: #C5A55A; background: transparent; cursor: pointer; transition: background 0.2s, color 0.2s; text-decoration: none; }
    .btn:hover { background: #C5A55A; color: #0D1B2A; text-decoration: none; }
    .btn--filled { background: #C5A55A; color: #0D1B2A; }
    .btn--filled:hover { background: #d4b56a; color: #0D1B2A; }
    .footer-legal { background-color: #0D1B2A; border-top: 1px solid rgba(197, 165, 90, 0.08); padding: 40px 24px; }
    .footer-legal__inner { max-width: 1200px; margin: 0 auto; display: flex; flex-direction: column; gap: 8px; }
    .footer-legal p { font-size: 0.75rem; color: rgba(232, 228, 222, 0.3); line-height: 1.6; }
    @media (max-width: 768px) {
      .nav__links { gap: 16px; }
      .nav__links a { font-size: 0.72rem; }
      .breadcrumb { padding-top: 100px; }
      .article-header { padding: 32px 0 48px; }
      .article-body p { font-size: 0.98rem; }
      .key-stat__number { font-size: 2.4rem; }
      .pull-quote { padding: 16px 20px; }
    }
  </style>
</head>
<body>

  <!-- ═══ Navigation ══════════════════════════════════════════════════════ -->
  <nav class="nav">
    <a href="/" class="nav__logo">Élan<span>.</span></a>
    <ul class="nav__links">
      <li><a href="/">Home</a></li>
      <li><a href="/blog.html" class="active">Articles</a></li>
      <li><a href="/faq.html">FAQ</a></li>
      <li style="margin-left:8px;border-left:1px solid rgba(197,165,90,0.25);padding-left:16px;display:flex;gap:12px;"><a href="/et.html" style="font-size:0.7rem;">EST</a> <a href="/ukk.html" style="font-size:0.7rem;">FIN</a> <a href="/voprosy.html" style="font-size:0.7rem;">RUS</a></li>
      <li><a href="/#consultation" class="btn" style="padding: 10px 20px; font-size: 0.72rem;">Book a Consultation</a></li>
    </ul>
  </nav>

  <!-- ═══ Breadcrumb ══════════════════════════════════════════════════════ -->
  <div class="breadcrumb">
    <div class="container">
      <nav class="breadcrumb__inner" aria-label="Breadcrumb">
        <span class="breadcrumb__item"><a href="/">Home</a></span>
        <span class="breadcrumb__sep">›</span>
        <span class="breadcrumb__item"><a href="/blog.html">Articles</a></span>
        <span class="breadcrumb__sep">›</span>
        <span class="breadcrumb__item breadcrumb__item--current">GLP-1 and Heart Health</span>
      </nav>
    </div>
  </div>

  <!-- ═══ Article Header ══════════════════════════════════════════════════ -->
  <header class="article-header">
    <div class="container">
      <div class="article-header__content">
        <span class="label">GLP-1 Medications · Cardiovascular Health</span>
        <h1>GLP-1 and Heart Health: What the SELECT Trial Actually Proved</h1>
        <div class="article-meta">
          <div class="article-meta__item">
            <strong>Dr. Ingmar Lindström</strong>
          </div>
          <div class="article-meta__dot"></div>
          <div class="article-meta__item">
            <time datetime="2026-03-01">March 1, 2026</time>
          </div>
          <div class="article-meta__dot"></div>
          <div class="article-meta__item">
            10 min read
          </div>
        </div>
      </div>
    </div>
  </header>

  <!-- ═══ Article Body ═════════════════════════════════════════════════════ -->
  <main class="article-body">
    <div class="container">
      <div class="article-body__inner">

        <div class="pull-quote">
          <p>"However difficult life may seem, there is always something you can do and succeed at." — Stephen Hawking</p>
        </div>

        <p>
          Hawking was talking about living with motor neurone disease. But the sentiment applies equally to cardiovascular risk — a domain where many people with obesity have been told, implicitly or explicitly, that the damage is done. That the risk is baked in. That medication can help you lose weight but probably won't touch your heart.
        </p>

        <p>The SELECT trial changed that narrative. And because it's been both overstated and understated depending on who's writing about it, I want to walk through what the trial actually showed — the numbers, the mechanism debates, the limitations, and what it means if you're sitting across from me in clinic.</p>

        <hr />

        <h2>What Was the SELECT Trial?</h2>

        <p>
          SELECT — Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity — was a randomised, double-blind, placebo-controlled trial published in the <em>New England Journal of Medicine</em> in 2023. It enrolled <strong>17,604 people</strong> across 41 countries. It is, to date, the largest cardiovascular outcomes trial ever conducted in people with obesity who did not have type 2 diabetes.
        </p>

        <p>
          The inclusion criteria matter for understanding the results. Every participant had pre-existing cardiovascular disease — prior heart attack, stroke, or symptomatic peripheral arterial disease — combined with a body mass index of 27 or above. No diabetes at baseline. Average age 61. The population was high-risk by design: these were people for whom a cardiovascular event was not a distant theoretical risk but a lived, documented reality.
        </p>

        <p>
          They were randomised to semaglutide 2.4 mg once weekly (the Wegovy dose) or placebo, with the primary endpoint being <strong>MACE</strong> — major adverse cardiovascular events — defined as death from cardiovascular causes, non-fatal heart attack, or non-fatal stroke. The median follow-up was 39.8 months, roughly three and a half years.
        </p>

        <hr />

        <h2>The Main Result: What HR 0.80 Actually Means</h2>

        <p>
          The headline finding was a <strong>20% relative reduction in MACE</strong> in the semaglutide group versus placebo. In statistical terms: hazard ratio 0.80, 95% confidence interval 0.72–0.90, p&lt;0.001. Highly statistically significant. The result was consistent across the pre-specified subgroups.
        </p>

        <div class="key-stat">
          <div class="key-stat__number">HR 0.80</div>
          <div class="key-stat__label">Hazard ratio for major cardiovascular events (MACE) in the SELECT trial — a 20% relative risk reduction over a median 39.8-month follow-up in 17,604 people with pre-existing cardiovascular disease and overweight or obesity, without diabetes.</div>
        </div>

        <p>
          To translate the hazard ratio into something tangible: the event rate in the placebo group was 8.0% over the trial period; in the semaglutide group it was 6.5%. That's an absolute risk reduction of 1.5 percentage points. The number needed to treat — the number of people who need to be on semaglutide for one MACE event to be prevented — was approximately 67 over about three and a half years.
        </p>

        <p>
          In cardiovascular pharmacology, those are meaningful numbers. Statins — the gold standard of cardiovascular risk reduction — achieved roughly comparable NNTs in secondary prevention populations at similar timepoints. The SELECT trial essentially positioned semaglutide alongside the most established cardiovascular medications we have, for a population that shares significant overlap.
        </p>

        <hr />

        <h2>The Mechanism Debate: Is This the Weight Loss Talking?</h2>

        <p>
          The most scientifically interesting — and clinically important — question the SELECT trial raises is: <em>why</em> does semaglutide reduce cardiovascular events? There are two broad hypotheses, and the trial wasn't designed to definitively separate them.
        </p>

        <h3>Hypothesis 1: It's the weight loss</h3>

        <p>
          Obesity drives cardiovascular risk through multiple mechanisms — hypertension, dyslipidaemia, insulin resistance, chronic low-grade inflammation, sleep apnoea, and others. Participants in the SELECT trial lost an average of 9.4% of body weight on semaglutide versus 0.9% on placebo. That's a meaningful difference. Weight loss at that magnitude is associated with improved blood pressure, triglycerides, HDL cholesterol, and inflammatory markers — all of which independently reduce cardiovascular risk.
        </p>

        <h3>Hypothesis 2: GLP-1 receptors have direct cardiac effects</h3>

        <p>
          GLP-1 receptors are expressed in cardiac tissue, and preclinical studies have demonstrated that GLP-1 receptor agonism reduces myocardial inflammation, improves endothelial function, and may have direct anti-atherosclerotic effects independent of weight or glycaemic changes. The prior LEADER trial (liraglutide, in type 2 diabetes) and SUSTAIN-6 trial (semaglutide, in type 2 diabetes) both showed cardiovascular benefit, suggesting the drug class has effects that extend beyond metabolic parameters.
        </p>

        <p>
          The SELECT trial cannot resolve this debate because it wasn't designed to. What it demonstrates is that the combination — this drug, administered this way, over this timeframe, in this population — produces a statistically and clinically significant reduction in cardiovascular events. The mechanism question matters for drug development and future trials; it matters less for the person sitting in front of me.
        </p>

        <hr />

        <h2>What the Trial Did Not Show</h2>

        <p>
          Rigorous interpretation requires acknowledging the limitations. SELECT showed cardiovascular benefit in a specific, high-risk secondary prevention population. It does not prove that semaglutide reduces cardiovascular events in:
        </p>

        <p>
          <strong>People without pre-existing cardiovascular disease.</strong> The trial enrolled only those with documented CVD. The question of primary prevention — preventing a first event — remains unanswered by this data. Trials in lower-risk populations are ongoing, but we don't have the evidence yet.
        </p>

        <p>
          <strong>People with type 2 diabetes.</strong> SELECT excluded diabetes at baseline. Prior trials (LEADER, SUSTAIN-6) covered that population separately. The mechanisms may overlap but the populations are different, and results should not be extrapolated uncritically between them.
        </p>

        <p>
          <strong>Short-term use.</strong> The median follow-up was nearly four years. The cardiovascular curves separated after approximately six months, suggesting that early use provides some benefit — but the magnitude of benefit observed reflects sustained therapy. What short-term use (six months, one year) does to cardiovascular risk in this population is not something SELECT can tell us.
        </p>

        <p>
          <strong>Other GLP-1 drugs at other doses.</strong> SELECT used semaglutide 2.4 mg. The class effect assumption — that all GLP-1 receptor agonists share this benefit — is biologically plausible but not proven at this dose and indication. Tirzepatide trials are underway (SURMOUNT-MMO); we await those results.
        </p>

        <hr />

        <h2>The Heart Failure Signal</h2>

        <p>
          One finding from SELECT deserves specific mention because it has generated significant clinical discussion: <strong>heart failure hospitalisation was reduced by 18%</strong> in the semaglutide group (HR 0.82, 95% CI 0.71–0.96). Heart failure is notoriously difficult to treat pharmacologically — most drug classes that reduce cardiovascular mortality paradoxically worsen heart failure outcomes. The fact that semaglutide reduced both MACE and heart failure events in the same trial is unusual and noteworthy.
        </p>

        <p>
          This finding aligns with the separate STEP-HFpEF trial (2023), which showed semaglutide substantially improved symptoms, exercise capacity, and body weight in people with heart failure with preserved ejection fraction — a condition for which effective treatment options are limited. These two datasets, read together, suggest a meaningful role for GLP-1 therapy in the management of cardiovascular-metabolic disease that extends beyond the traditional weight loss conversation.
        </p>

        <hr />

        <h2>The All-Cause Mortality Question</h2>

        <p>
          SELECT showed a non-significant trend toward reduced all-cause mortality (HR 0.81, 95% CI 0.65–1.01, p=0.07). The trial was not powered to detect mortality differences — MACE was the primary endpoint — and the confidence interval crosses 1.0, meaning we cannot conclude a mortality benefit from this data alone.
        </p>

        <p>
          This is an important nuance. Reducing cardiovascular events without a proven mortality reduction is still clinically meaningful — surviving a heart attack is better than dying from one, and each non-fatal event averted reduces disability, hospitalisation burden, and quality-of-life consequences. But claims that SELECT "proved semaglutide reduces death" are overstated. The mortality signal is encouraging; it is not proven.
        </p>

        <hr />

        <h2>What This Means in Clinical Practice</h2>

        <p>
          Before SELECT, semaglutide 2.4 mg was approved for weight management. That indication remains appropriate. What SELECT adds is a robust cardiovascular evidence base that changes the clinical calculus for a specific population — people with pre-existing cardiovascular disease and overweight or obesity.
        </p>

        <p>
          For those people, semaglutide is no longer "a weight loss drug that might help your heart." It is a cardiovascular medication with a proven MACE reduction, which also produces significant weight loss, which also improves a range of metabolic parameters. The framing matters, because it changes how we discuss the treatment with people and how we prioritise it in the context of other medications.
        </p>

        <p>
          In my practice, when I see someone with a history of myocardial infarction or stroke who also has obesity and has not responded adequately to lifestyle intervention, SELECT data is now part of the conversation — alongside lipid management, blood pressure control, and antiplatelet therapy. It belongs there. The evidence supports it.
        </p>

        <p>
          For people without established cardiovascular disease, the calculus is different. Weight loss benefits, metabolic improvements, and quality-of-life gains remain valid reasons to consider GLP-1 therapy. The SELECT-level cardiovascular evidence doesn't yet apply to them — but that doesn't make the medication less useful. It just means the conversation is led by different data.
        </p>

        <hr />

        <h2>The Physician's Summary</h2>

        <p>
          SELECT was a well-conducted, large, pre-registered trial with a clinically meaningful result. A 20% relative reduction in MACE over three and a half years, in a high-risk secondary prevention population, using a medication that also produces significant weight loss, is a landmark finding. It is not a cure. It is not infinite protection. And it applies specifically to people who fit the trial's population profile.
        </p>

        <p>
          What the trial genuinely proved is that semaglutide, used consistently and supervised appropriately, meaningfully reduces the probability of a second heart attack or stroke in people with pre-existing cardiovascular disease and overweight or obesity. For that population — and there are many millions of them — that evidence should change clinical practice.
        </p>

        <p>
          The question of <em>whether</em> this medication belongs in a treatment plan is increasingly settled for that group. The question worth spending clinical time on is <em>how</em> to use it well — at what dose, with what co-interventions, and within what programme of ongoing support.
        </p>

        <!-- ═══ Sources ═══════════════════════════════════════════════════ -->
        <div class="article-sources">
          <span class="sources-label">Sources</span>
          <p>Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." <em>New England Journal of Medicine</em>, 2023;389:2221–2232. (SELECT trial, n=17,604)</p>
          <p>Marso SP, Daniels GH, Brown-Frandsen K, et al. "Liraglutide and cardiovascular outcomes in type 2 diabetes." <em>NEJM</em>, 2016. (LEADER trial)</p>
          <p>Marso SP, Bain SC, Consoli A, et al. "Semaglutide and cardiovascular outcomes in patients with type 2 diabetes." <em>NEJM</em>, 2016. (SUSTAIN-6 trial)</p>
          <p>Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. "Semaglutide in patients with heart failure with preserved ejection fraction and obesity." <em>NEJM</em>, 2023. (STEP-HFpEF trial)</p>
        </div>

        <!-- ═══ Back Link ═════════════════════════════════════════════════ -->
        <a href="/blog.html" class="back-link">← Back to Articles</a>

      </div>
    </div>
  </main>

  <!-- ═══ Footer CTA ══════════════════════════════════════════════════════ -->
  <section class="footer-cta">
    <span class="label">Consultation</span>
    <h2>Managing Cardiovascular Risk on GLP-1 Therapy?</h2>
    <p class="footer-cta__sub">
      A 45-minute consultation to review your cardiovascular risk profile, discuss the SELECT trial evidence, and build a supervised programme that integrates GLP-1 therapy with your broader cardiac care.
    </p>
    <a href="tel:+37252999399" class="btn btn--filled">Call +372 52 99939</a>
  </section>

  <!-- ═══ Footer Legal ════════════════════════════════════════════════════ -->
  <footer class="footer-legal">
    <div class="footer-legal__inner">
      <p>© 2026 Élan Clinic · Elan Clinic OÜ · Reg 17338832 · Medical licence L07470 · Sepapaja 12/1, Tallinn 11415</p>
      <p>This article is for informational purposes only and does not constitute medical advice. Consult your physician before changing any medication or health programme.</p>
    </div>
  </footer>

</body>
</html>
